Tirabrutinib vs R-TMZ in Relapsed/Refractory PCNSL: IGNITE Study Launched
The IGNITE study is evaluating tirabrutinib's efficacy and safety against the R-TMZ regimen in relapsed/refractory PCNSL.
Company
Pharmaceutical intelligence for Ono Pharmaceutical with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No signals indexed for this entity yet.
No signals indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.